You are here: Industry Insights > schizophrenia

News List

Wisdom Linked to Cognitive Performance in Schizophrenia drugs
February 15, 2019
For people with schizophrenia (PwS), wisdom is associated with better cognitive performance, according to a study published online Feb. 14 in Schizophrenia Research.....
Mental health services falling behind rest of NHS – report pharmaphorum
January 15, 2019
Mental health services in the UK are falling behind physical health services because of outdated commissioning services in the National Health Service, according to a new report.
Sumitomo Dainippon announces good results from trial of its lead drug pharmaceutical-technology
January 14, 2019
Japan-based Sumitomo Dainippon Pharma has published positive results from the phase III JEWEL trial into its drug Latuda (lurasidone hydrochloride) for patients with schizophrenia.....
Perseris Now Available in the U.S. for the Treatment of Schizophrenia in Adults americanpharmaceuticalreview
November 20, 2018
Indivior announced that Perseris (risperidone) for extended-release injectable suspension is now available in the United
Researchers use polygene scores to treat psychiatric disorders biospectrum
November 06, 2018
Researchers used genetic tests to predict ultimate response to medications in patients suffering their first episode of schizophrenia. Rather than testing for a single gene, investigators used a relatively new approach called "polygenic risk scores.
Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia fiercebiotech
August 03, 2018
Karuna Pharmaceuticals has the cash it needs to start mid-stage trials of an Eli Lilly drug, shelved because of side effects, as part of a combination therapy for schizophrenia and Alzheimer’s.
Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3 pharmafile
August 02, 2018
It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) for the treatment of schizophrenia in adults, but its subsidiary’s investigational treatment guadecitabine failed to achieve
Indivior secures FDA approval for Perseris to treat schizophrenia pharmaceutical-technology
August 01, 2018
Specialty pharmaceutical company Indivior has secured the US Food and Drug Administration (FDA) approval for the use of its Perseris (risperidone) to treat adults suffering from schizophrenia.
Biogen buys Pfizer’s schizophrenia drug pharmatimes
July 24, 2018
Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million.
FDA approves Aristada Inito for the initiation of Aristada for schizophrenia europeanpharmaceuticalreview
July 05, 2018
Novel regimen enables physicians to fully dose up to two months of Aristada treatment on day one…

Previous page 1 2 3 4 5 Next page